AC Immune SA (ACIU) Institutional Buying & Selling Tracker (Q2 2026)

ACIU ranks #6558 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ACIU is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

43 institutions disclose a position in ACIU, but none treat it as a major bet — even Bvf Inc/il, its most concentrated holder, allocates just 1.2% of its own portfolio to it.

Barclays PLC has added to its ACIU position for two straight quarters, increasing it by $8.8K to reach $17.3K today.

Bvf Inc/il has trimmed its ACIU position for two straight quarters, cutting it by $15.1M while still holding $47.2M.

ACIU reported a net loss of $79.5M over the trailing twelve months.

• Not yet profitable — net loss of $79.5M over the trailing twelve months
• Revenue declined 1.6% year over year
• Net income declined year over year, from -$71.9M to -$79.5M
• Operating cash flow was negative, using $69.3M in cash
• Current ratio of 1.02x — below the conventional 1.5x liquidity buffer
• Liabilities run 2.44x equity — a highly leveraged balance sheet worth noting